LinkedInNancy Parenteau
Nancy Parenteau

Nancy Parenteau

Location
Benson, Vermont
Industry
Biotechnology
Previous
  1. Amaranth Bio, Inc.,
  2. Organogenesis Inc.
294connections

Join LinkedIn & access Nancy's full profile

Join LinkedIn & access Nancy's full profile. It's free!

As a LinkedIn member, you'll join 300 million other professionals who are sharing connections, ideas, and opportunities.

  • See who you know in common
  • Get introduced
  • Contact Nancy directly
294connections
View full profile

Background

Experience

Co-founder, President and CEO

Amaranth Bio, Inc.
(3 years)Greater Boston Area

Chief Scientific Officer/SVP R&D

Organogenesis Inc.
(6 years)

Publications

Driving the Bumpy Road to Commercialization(Link)

Tissue Engineering, Part A
January 2014

Tissue engineering has always had an applied focus and there is hardly an academic publication that does not mention the applicability of its findings to the future development of a medical product. I have been involved in the industry side of tissue engineering from the start, pursuing a variety of applications, some making it to the marketplace. There have been many lessons that I have learned from direct experience (mistakes and successes), observation, through advising others, and now, in developing innovative ways to identify and eliminate the regenerative cell populations within a tumor. This brief overview of some of these lessons is written with the next generation of pioneering product developers in mind: the biologists, biochemists and engineers who will dedicate their careers to driving medical and commercial progress in tissue engineering.

Meeting the Need for Regenerative Therapies I: Target-Based Incidence and its Relationship to US Spending, Productivity and Innovation

Tissue Engineering, Part B
January 2012
Authors:

Commercialization of engineered tissue products(Link)

In: Advanced Wound Repair Therapies, Woodhead Publishing, London
2011

Health care is increasingly evidence-based as products compete for limited dollars. Advanced wound therapies are particularly at risk because of the paucity of Level I evidence to support their effectiveness and economic advantage over good wound care. This chapter looks for lessons from the commercialization of advanced products and product concepts over the last 30 years. For advanced wound therapies to be adopted, they will have to demonstrate clinical and cost effectiveness capable of driving practice from the persistent approach of wound care and management to one of active wound healing.

Commercial development of cell-based therapeutics: strategic considerations along the drug to tissue spectrum

Regenerative Medicine
July 2009

The engineering of tissues using progenitor cells

Current Topics in Developmental Biology
2004
Authors:

Immunotherapy Demystified: Investing in High Risk, High Reward Opportunities in Cancer therapeutics(Link)

The Parenteau BioConsultants and BioRankings Alliance
December 2009

Educational free ebook for investors and lay people wanting to learn more about cancer immunotherapies.

Authors:

Skills

  • Life Sciences
  • Strategic Planning
  • Product Development
  • Medical Devices
  • Business Planning
  • Research
  • Start-ups
  • Business Strategy
  • R&D
  • Team Building
  • Market Research
  • Due Diligence
  • Writing
  • Coaching
  • Lifesciences
  • Biotechnology
  • Commercialization
  • Cell Biology
  • Cell Culture
  • Stem Cells
  • Management
  • Entrepreneurship
  • Strategy
  • Corporate Development
  • Tissue Engineering
  • Biopharmaceuticals
  • Technology Transfer
  • Drug Development
  • Drug Discovery
  • See 14+  See less

View Nancy's full profile to...

  • See who you know in common
  • Get introduced
  • Contact Nancy directly

Not the Nancy Parenteau you're looking for? View more

Insights


People Also Viewed


LinkedIn member directory:

  1. a
  2. b
  3. c
  4. d
  5. e
  6. f
  7. g
  8. h
  9. i
  10. j
  11. k
  12. l
  13. m
  14. n
  15. o
  16. p
  17. q
  18. r
  19. s
  20. t
  21. u
  22. v
  23. w
  24. x
  25. y
  26. z
  27. more